NCT01990326暂停2 期
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of XAF5 Gel for Reduction of Submental Fat
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 暂停
- 入组人数
- 27
- 主要终点
- Frequency of adverse events
研究概览
简要总结
This study will test the effects of XAF5 Gel (applied to skin each night for 6 weeks) on excess submental fat, also known as double chin. The study will also assess the safety and tolerability of XAF5 Gel.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
XAF5 Gel
Experimental
The patient will apply XAF5 Gel to the skin of the submental area once a night.
干预措施: XAF5 Gel (Drug)
Placebo Gel
Placebo Comparator
The patient will apply a Placebo Gel to the skin of the submental area once a night.
干预措施: Placebo Gel (Drug)
结局指标
主要结局
Frequency of adverse events
时间窗: From Day 1 to Day 57
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)Lower Eyelid Steatoblepharon (Excess Eyelid Fat)NCT02230761Topokine Therapeutics, Inc.90
已完成
2 期
Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)Painful Lumbosacral RadiculopathyNCT06176196Vertex Pharmaceuticals Incorporated218
已完成
2 期
A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)Postherpetic NeuralgiaNCT01195636Xenon Pharmaceuticals Inc.70
已完成
3 期
A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)Diabetes Mellitus, Type 2NCT01733758GlaxoSmithKline494
已完成
2 期
Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X SyndromeFragile X SyndromeNCT01357239Novartis Pharmaceuticals139